A Real‐World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma in the United States
Authors:
Open Access
Abstract
Background: Tafasitamab, a CD19‐targeting immunotherapy, is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplant. This real‐world study describes patient characteristics, treatment patterns, and outcomes associated with tafasitamab for R/R DLBCL across US practice settings. Methods: A retrospective physician‐abstracted chart review was conducted among US adults initiating tafasitamab (with/without lenalidomide) for R/R DLBCL as part of routine clinical care. Data were summarized using descriptive statistics. Cox proportional hazards‐based analyses were performed to determine baseline characteristics associated with real‐world progression‐free survival and overall survival. Results: Twenty‐three physicians (83% community physicians) provided data on 181 patients (64% White; median follow‐up since initiation, 14.7 months) meeting eligibility criteria. Most patients (72%) received tafasitamab as second‐line (2L) therapy. Real‐world overall response rate (95% CI) to tafasitamab was 73.5% (67.0–79.9). Median (95% CI) real‐world progression‐free survival and overall survival from tafasitamab initiation were 11.3 (9.8–13.6) and 24.8 (17.8–NE) months, respectively. In multivariable Cox proportional hazards‐based analyses, tafasitamab use in third‐line to fifth‐line (3L–5L) (vs. 2L), bulky disease (vs. non‐bulky), Ann Arbor Stage III–IV (vs. stage I–II), and increasing Charlson Comorbidity Index scores were determined as factors associated with increased progression risk. In addition, increasing age, tafasitamab in 3L–5L (vs. 2L), bulky disease (vs. non‐bulky), and Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2 (vs. < 2) were associated with higher mortality risk. Conclusion: This analysis of a diverse US population who received tafasitamab for R/R DLBCL predominantly in community practice settings supports the clinical benefit of tafasitamab. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.Keywords
Funding Information
- Incyte
This publication has 16 references indexed in Scilit:
- A real-world disproportionality analysis of colchicine: data mining of the public version of FDA Adverse Event Reporting SystemExpert Opinion on Drug Safety, 2024
- Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphomaLeukemia & Lymphoma, 2024
- Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyBlood, 2023
- Epidemiology and etiology of diffuse large B-cell lymphomaSeminars in Hematology, 2023
- P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENSHemaSphere, 2023
- ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell LymphomaTransplantation and Cellular Therapy, 2023
- Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trialsAmerican Journal of Hematology, 2021
- 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and managementAmerican Journal of Hematology, 2021
- Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical TrialsJAMA Network Open, 2021
- Racial differences in three major NHL subtypes: Descriptive epidemiologyCancer Epidemiology, 2015